I-Mab
IMABNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for IMAB. That does not mean none is planned.
Get an email about IMAB's next catalysts
Track I-Mab (IMAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
TJ003234
Coronavirus Disease 2019 COVID-19
TJ301
Active Ulcerative Colitis
TJ004309
Ovarian Cancer
Givastomig
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TJ003234 | Phase 3 | Coronavirus Disease 2019 COVID-19 | - | - |
TJ301 | Phase 2 | Active Ulcerative Colitis | - | - |
TJ004309 | Phase 2 | Ovarian Cancer | - | - |
Givastomig | Phase 2 | Solid Tumor | - | - |
Frequently asked questions
What is in I-Mab's drug pipeline?β
CatalystAlert tracks 4 drug candidates in I-Mab's (IMAB) pipeline across Phase 3, Phase 2. Its lead program is TJ003234 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is I-Mab's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for I-Mab (IMAB) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMAB biotech catalysts?β
Add IMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow I-Mab's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
